N
ATYR

Natixis’s aTyr Pharma ATYR Stock Holding History

Natixis’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-280
Closed -$219 – 1357
2025
Q4 		$219 Buy
+280
New +$230 ﹤0.01% 1095

Other funds holding ATYR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Natixis's ATYR Position: Q1 2026 in Review

Natixis sold out of aTyr Pharma (ATYR) in Q1 2026, closing a stake of 280 shares — an estimated $219 sold.

Natixis first reported a position in ATYR in Q4 2025 and held it in 1 quarter. The position peaked at $219 in Q4 2025. 111 funds tracked by Wall St. Rank hold ATYR as of Q1 2026.

  • Natixis reported no remaining aTyr Pharma position as of Q1 2026 after selling out during the quarter.
  • Natixis sold 280 aTyr Pharma shares in Q1 2026, an estimated $219.
  • Natixis first reported a position in aTyr Pharma in Q4 2025 and held it in 1 quarter.
  • Natixis's aTyr Pharma position peaked at $219 in Q4 2025.
  • 111 funds tracked by Wall St. Rank held aTyr Pharma as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.